An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) will host a conference call and live webcast on May 2, 2024, to report its first quarter 2024 financial results and business highlights.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) ospiterà una teleconferenza e una trasmissione web in diretta il 2 maggio 2024 per presentare i risultati finanziari del primo trimestre del 2024 e gli aspetti salienti dell'attività.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) organizará una llamada de conferencia y una transmisión web en vivo el 2 de mayo de 2024 para informar sobre sus resultados financieros del primer trimestre de 2024 y los aspectos destacados del negocio.
Agios Pharmaceuticals, Inc. (나스닥: AGIO)는 2024년 5월 2일에 2024년도 1분기 재무 결과와 사업 하이라이트를 보고하기 위한 컨퍼런스 콜과 라이브 웹캐스트를 주최할 예정입니다.
Agios Pharmaceuticals, Inc. (Nasdaq : AGIO) organisera une conférence téléphonique et une webdiffusion en direct le 2 mai 2024 pour présenter ses résultats financiers du premier trimestre 2024 et les points forts de l'entreprise.
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) wird am 2. Mai 2024 eine Telefonkonferenz und einen Live-Webcast veranstalten, um seine Finanzergebnisse für das erste Quartal 2024 und die Geschäftshöhepunkte zu berichten.
Positive
None.
Negative
None.
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.
About Agios Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, MDS-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts: Investor Contact Chris Taylor, VP, Investor Relations and Corporate Communications Agios Pharmaceuticals IR@agios.com
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible